Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab for Refractory Diabetic Macular Edema (IBEME Study) - Related Studies

Intravitreal Triamcinolone Acetonide Versus Intravitreal Bevacizumab for Refractory Diabetic Macular Edema (IBEME Study)

This study is ongoing, but not recruiting participants.

Study NCT00468351. Last updated on May 1, 2007. Information provided by University of Sao Paulo

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Diabetic Macular Edema

2	Additional conditions recognized in this trial
		Edema
		Macular Edema

3	More general conditions related to this trial
		Eye Diseases
		Macular Degeneration
		Retinal Degeneration
		Retinal Diseases
		Signs and Symptoms

4	Additional drug interventions recognized in this trial
		Bevacizumab
		Triamcinolone
		Triamcinolone Acetonide
		Triamcinolone diacetate
		Triamcinolone hexacetonide

5	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-Inflammatory Agents
		Antineoplastic Agents
		Enzyme Inhibitors
		Glucocorticoids
		Growth Inhibitors
		Growth Substances
		Hormones
		Hormones, Hormone Substitutes, and Hormone Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		University of Sao Paulo